{ "id": "epmf6damhn", "slug": "lymph-node-mapping", "title": "Lymph node mapping", "updated": "2026-10-21", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.clinical-surgery", "label": "Surgery and surgical specialties", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-surgery" }, { "id": "life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro", "label": "Plastic, reconstructive, and oncologic surgery procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro", "label": "Non-geographic · 1946 to 2000: Plastic, reconstructive, and oncologic surgery procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-surgery", "label": "Surgery and surgical specialties", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-surgery" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro", "label": "Plastic, reconstructive, and oncologic surgery procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro" } ] } ], "excerpt": "Lymph node mapping is a surgical and imaging technique that identifies the first lymph node draining a tumor, guiding biopsy and staging in breast cancer and melanoma.", "snippet": "Lymph node mapping is a surgical and imaging technique that identifies the first lymph node draining a tumor, guiding biopsy and staging in breast cancer and melanoma.", "node": "life.health.clinical.clinical-surgery.plastic-reconstructive-and-oncologic-surgery-pro", "markdown": "# Lymph node mapping\n\nLymph node mapping is a surgical and imaging technique that identifies and marks the lymph nodes draining a tumor, above all the first draining (sentinel) node, so that a small sample can be staged pathologically and used to decide between biopsy alone, further dissection, radiotherapy, or systemic therapy. The procedure produces a mapped, excised sentinel node (SLN) with a pathological nodal status, and that status drives staging, eligibility for adjuvant drug treatment, and the extent of axillary or regional surgery.[1](https://ascopubs.org/doi/10.1200/JCO-25-00099) • [2](https://link.springer.com/article/10.1007/s12254-026-01108-0)\n\n| Key fact | Detail |\n|---|---|\n| Sentinel node concept | The first draining node of a tumor field; introduced for penile carcinoma by Ramon M. Cabanas in 1977[3](https://doi.org/10.1002/1097-0142%28197702%2939:2<456::aid-cncr2820390214>3.0.co;2-i) |\n| Melanoma detection | SLNs detected in more than 95% of patients, ~98% accuracy in experienced hands[4](https://www.ncbi.nlm.nih.gov/books/NBK6977/); meta-analytic mapping success 98.1%, average false-negative rate (FNR) 12.5%[5](https://ascopubs.org/doi/10.1200/JCO.2010.33.1884) |\n| Breast detection | Identification 93–98% with 95–99% correct nodal status prediction[4](https://www.ncbi.nlm.nih.gov/books/NBK6977/); pooled FNR 8.61%[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469260/) |\n| Tracers | Radiocolloids, blue dyes, ICG with near-infrared fluorescence, superparamagnetic iron oxide (SPIO), and Tc-99m tilmanocept[7](https://www.breastsurgeons.org/docs/statements/asbrs-technical-considerations-for-axillary-surgery-in-breast-cancer-patients-2026-02-24.pdf) |\n| Dual vs single tracer | Breast FNR 5.9% with dye plus tracer versus 8.6% with dye alone[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469260/) |\n| Standard of care | Penile cancer: standard of care; incorporated in clinical practice for endometrial, cervical, and vulvar cancer[8](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1422549/full) |\n| Recent change | 2025 ASCO guidance recommends against routine SLNB in select low-risk postmenopausal patients[1](https://ascopubs.org/doi/10.1200/JCO-25-00099) |\n\n## How it works\n\nThe sentinel node is the first lymph node on the drainage pathway from a primary tumor. Because metastasis travels through the lymphatic system in sequence, examining this node predicts the status of the whole regional basin: in Giuliano and colleagues' prospective breast cancer trial, the SLN was the only site of axillary disease in 12 of 18 (67%) patients with metastases, and no \"skip\" metastases were seen, defined as a negative SLN with higher nodes positive.[9](https://pubmed.ncbi.nlm.nih.gov/8946902/)\n\nTracer behavior depends on particle size. The ideal particle for lymphoscintigraphy is approximately 50–70 nm; particles smaller than a few nanometers leak into blood capillaries, and particles larger than 100 nm persist in the interstitial space instead of draining.[10](https://geiselmed.dartmouth.edu/radiology/wp-content/uploads/sites/47/2025/12/Lymphoscintigraphy-for-educ.-lymph-.pdf) A radiocolloid should therefore balance fast lymphatic drainage with retention in the SLN.[11](https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2013/Final%20Breast%20Sentinel%20Node%20Guideline.pdf) Tilmanocept works differently: it is a 7 nm synthetic molecule whose dextran backbone carries mannose ligands that bind CD206 on macrophages and dendritic cells, giving rapid transit plus selective retention.[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967737/)\n\n## How it is done\n\nFor radioguided mapping, filtered Tc-99m sulfur colloid (typically 1–4 mCi in 0.5–1.0 mL for adults; activity 0.1–10 mCi adjusted to the injection-to-surgery interval) is injected around the tumor or intradermally, and SLNs are generally visualized on lymphoscintigraphy within 1–2 hours, with surgery within 2–30 hours of injection.[10](https://geiselmed.dartmouth.edu/radiology/wp-content/uploads/sites/47/2025/12/Lymphoscintigraphy-for-educ.-lymph-.pdf) • [11](https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2013/Final%20Breast%20Sentinel%20Node%20Guideline.pdf) • [13](https://www.ncbi.nlm.nih.gov/books/NBK563213/) SPECT/CT adds nodes not visible on planar images and is recommended after prior breast surgery or radiotherapy.[14](https://www.mdpi.com/2075-4418/14/3/252)\n\nBlue dye (2–5 mL) is injected 10–20 minutes before surgery; nodes are colored within 5–15 minutes, washout begins after about 45 minutes, and five minutes of massage enhances dye movement.[11](https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2013/Final%20Breast%20Sentinel%20Node%20Guideline.pdf) Intraoperatively, the surgeon removes all blue nodes, all palpably suspicious nodes, and any node with counts at least 10% of the hottest node (the 10% rule); a typical yield is 1–4 nodes, median 2, since removing more than 3–4 does not improve staging accuracy and raises lymphedema risk.[7](https://www.breastsurgeons.org/docs/statements/asbrs-technical-considerations-for-axillary-surgery-in-breast-cancer-patients-2026-02-24.pdf)\n\nFor ICG fluorescence, 1 mL of Infracyanine (25 mg/10 mL) is injected subdermally or periareolarly after anesthesia, followed by five minutes of massage; ICG bound to plasma albumin emits fluorescence under 806 nm light, allowing real-time tracking until no residual fluorescence remains.[15](https://www.ovid.com/journals/anzsu/pdf/10.1111/ans.70122~how-to-do-indocyanine-green-fluorescenceguided-axillary) Tilmanocept is dosed at 18.5 MBq (0.5 mCi) and 50 μg, given at least 15 minutes before mapping.[16](https://tech.snmjournals.org/content/43/2/87)\n\n## Origin\n\nThe term \"sentinel node\" was used by Ernest A. Gould and colleagues in 1960 for parotid cancer.[17](https://doi.org/10.1002/1097-0142%28196001/02%2913:1<77::aid-cncr2820130114>3.0.co;2-d) Ramon M. Cabanas applied the concept to penile carcinoma in 1977 using lymphangiograms via the dorsal lymphatics of the penis.[3](https://doi.org/10.1002/1097-0142%28197702%2939:2<456::aid-cncr2820390214>3.0.co;2-i) • [18](https://wjso.biomedcentral.com/articles/10.1186/1477-7819-2-9) After a feline model demonstrated feasibility (Wong, Cagle, and Morton, 1991),[19](https://doi.org/10.1097/00000658-199111000-00015) [Donald L. Morton](https://www.edgepedia.org/donald-l-morton) reported intraoperative [lymphatic mapping](https://www.edgepedia.org/lymphatic-mapping) with intradermal isosulfan blue for melanoma in 1992, identifying a blue-stained SLN in 194 of 237 (82%) basins with a 5% false-negative rate.[20](https://doi.org/10.1001/archsurg.1992.01420040034005) • [21](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/canjclin.56.5.292) Armando E. Giuliano and colleagues adapted the technique to breast cancer in 1994.[22](https://doi.org/10.1097/00000658-199409000-00015) Radioactive tracers with gamma probes were subsequently added to the technique.[18](https://wjso.biomedcentral.com/articles/10.1186/1477-7819-2-9)\n\n## Variants\n\nTracers differ in mechanism and performance. Radiopharmaceuticals include Tc-99m albumin nanocolloid (5–100 nm), Tc-99m sulfur colloid (15–5000 nm, usually filtered), and Tc-99m [antimony trisulfide](https://www.edgepedia.org/antimony-trisulfide) (3–30 nm).[14](https://www.mdpi.com/2075-4418/14/3/252) In breast cancer, pooled FNRs were 8.6% for dye alone, 7.4% for tracer alone, and 5.9% for dye plus tracer (\\( p = 0.018 \\) for dye-only versus dual).[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469260/)\n\nICG fluorescence is a small water-soluble molecule that binds lymph proteins and reaches the closest nodes within minutes; it suffers aggregation-caused quenching, so dilution with albumin or Voluven is used to control diffusion.[23](https://www.mdpi.com/2072-6694/15/24/5755) A meta-analysis of 19 studies found a pooled ICG detection rate of 0.98 and sensitivity of 0.92.[24](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0155597) Tc-99m tilmanocept detected all 45 melanoma-positive SLNs versus 36 of 45 (80%) for blue dye, with an FNR of 2.6% versus 9.8% for sulfur colloid.[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967737/) SPIO tracers, compared in the noninferiority SentimagIC trial by Michael D. Alvarado and colleagues (2019), remain detectable for up to 30 days, permitting delayed surgery.[25](https://doi.org/10.1245/s10434-019-07577-4) • [7](https://www.breastsurgeons.org/docs/statements/asbrs-technical-considerations-for-axillary-surgery-in-breast-cancer-patients-2026-02-24.pdf)\n\n## Applications\n\nMapping is standard of care in breast cancer, melanoma, and penile cancer, and is incorporated in practice for endometrial, cervical, and vulvar cancer; results in ovarian cancer are conflicting.[8](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1422549/full) The ASCO–SSO melanoma guideline endorses SLNB for intermediate-thickness (1–4 mm) melanoma.[26](https://llusurgonc.org/images/DOWNLOADS/SENTINEL_ARTICLE/Melanoma/Nodal/SSO-ASCO-Melanoma-SLNB-guidelines_JCO2012.pdf) In prostate cancer with Ga-68 PSMA imaging, index-lesion injection found 32.6% of harvested sentinel nodes outside extended dissection fields, with 94.4% sensitivity.[8](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1422549/full) In head and neck squamous cell carcinoma, concomitant radio- and fluorescence-guided biopsy with ICG-Tc-99m-nanocolloid has been used, and SPECT/CT identified additional SLNs in 55% of head and neck cases versus planar imaging.[27](https://doi.org/10.1007/s00259-012-2129-5) • [16](https://tech.snmjournals.org/content/43/2/87)\n\n## Limitations and alternatives\n\nFailure modes include significant axillary disease burden, extranodal extension, and bulky tumors, with surgeon experience the most important predictor of successful identification.[28](https://www.ajronline.org/doi/full/10.2214/AJR.19.22022) Aberrant drainage occurs in 40–43% of patients with prior axillary procedures; peritumoral injection finds internal mammary nodes in 20–30% of cases versus under 3% after periareolar injection.[7](https://www.breastsurgeons.org/docs/statements/asbrs-technical-considerations-for-axillary-surgery-in-breast-cancer-patients-2026-02-24.pdf) • [14](https://www.mdpi.com/2075-4418/14/3/252) Blue dye can cause anaphylaxis requiring resuscitation in 0.5–1.0% of patients.[11](https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2013/Final%20Breast%20Sentinel%20Node%20Guideline.pdf) Radiotracer use requires a nuclear medicine facility; limited data suggest Tc-99m sulfur colloid is safe in pregnancy under 30 weeks while isosulfan blue and methylene blue are not.[23](https://www.mdpi.com/2072-6694/15/24/5755) • [1](https://ascopubs.org/doi/10.1200/JCO-25-00099)\n\nCompared with axillary dissection, SLNB alone was noninferior in ACOSOG Z0011 (10-year overall survival 86.3% vs 83.6%, noninferiority p=.02), and MSLT-I reported 10.1% complications after SLN biopsy versus 32.7% after completion dissection in melanoma.[1](https://ascopubs.org/doi/10.1200/JCO-25-00099) • [26](https://llusurgonc.org/images/DOWNLOADS/SENTINEL_ARTICLE/Melanoma/Nodal/SSO-ASCO-Melanoma-SLNB-guidelines_JCO2012.pdf) After neoadjuvant chemotherapy, performance worsens: ACOSOG Z1071 found 92.7% identification and 12.6% FNR, improving to 10.8% with dual tracer and 9.1% when three or more SLNs were removed.[28](https://www.ajronline.org/doi/full/10.2214/AJR.19.22022) Targeted axillary dissection (TAD), which adds removal of the biopsy-clipped node, reduced FNR to 2.0% versus 10.1% for SLNB alone in the study by Abigail S. Caudle and colleagues (2016).[29](https://doi.org/10.1200/jco.2015.64.0094) • [28](https://www.ajronline.org/doi/full/10.2214/AJR.19.22022) In selected low-risk patients, omission is now an alternative: the SOUND trial (local-regional relapse 1.7% vs 1.6%) and INSEMA trial (5-year invasive disease-free survival 91.9% without SLNB vs 91.7% with, HR 0.91) showed noninferiority of omitting axillary surgery.[2](https://link.springer.com/article/10.1007/s12254-026-01108-0) • [1](https://ascopubs.org/doi/10.1200/JCO-25-00099)\n\nSince late 2023, the 2025 ASCO update recommends against routine SLNB in postmenopausal patients aged 50 or older with grade 1–2, \\( \\leq 2 \\) cm, hormone receptor-positive, HER2-negative tumors, negative axillary ultrasound, undergoing [breast-conserving therapy](https://www.edgepedia.org/breast-conserving-therapy).[1](https://ascopubs.org/doi/10.1200/JCO-25-00099) The Japanese Breast Cancer Society recommends ICG as a safe alternative to radioisotope, and hybrid ICG-technetium tracers and AI-assisted fluorescence mapping are under exploration.[23](https://www.mdpi.com/2072-6694/15/24/5755) • [30](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1817708/full)\n\n## References\n\n1. [Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update (2025)](https://ascopubs.org/doi/10.1200/JCO-25-00099)\n2. [Current surgical standards in the management of the axilla (memo - Magazine of European Medical Oncology, 2026)](https://link.springer.com/article/10.1007/s12254-026-01108-0)\n3. [An approach for the treatment of penile carcinoma (Cancer, 1977)](https://doi.org/10.1002/1097-0142%28197702%2939:2<456::aid-cncr2820390214>3.0.co;2-i)\n4. [Sentinel node detection (NCBI Bookshelf)](https://www.ncbi.nlm.nih.gov/books/NBK6977/)\n5. [Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta-Analysis (JCO)](https://ascopubs.org/doi/10.1200/JCO.2010.33.1884)\n6. [The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis (Pesek et al.)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3469260/)\n7. [ASBrS Resource Guide on Technical Considerations for Axillary Surgery in Breast Cancer Patients (2026)](https://www.breastsurgeons.org/docs/statements/asbrs-technical-considerations-for-axillary-surgery-in-breast-cancer-patients-2026-02-24.pdf)\n8. [Editorial: Sentinel lymph node mapping: current applications and future perspectives (Frontiers in Medicine, 2024)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1422549/full)\n9. [Lymphatic mapping and sentinel node biopsy in the patient with breast cancer (Giuliano et al., 1996, Arch Surg)](https://pubmed.ncbi.nlm.nih.gov/8946902/)\n10. [Nuclear Medicine Lymphoscintigraphy: Applications and Technical Overview](https://geiselmed.dartmouth.edu/radiology/wp-content/uploads/sites/47/2025/12/Lymphoscintigraphy-for-educ.-lymph-.pdf)\n11. [The EANM and SNMMI Practice Guideline for Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer](https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2013/Final%20Breast%20Sentinel%20Node%20Guideline.pdf)\n12. [Detection of melanoma, breast cancer and head and neck squamous cell cancer sentinel lymph nodes by Tc-99m Tilmanocept (Lymphoseek)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967737/)\n13. [Lymphoscintigraphy, StatPearls (NCBI Bookshelf)](https://www.ncbi.nlm.nih.gov/books/NBK563213/)\n14. [Update on Sentinel Lymph Node Methods and Pathology in Breast Cancer (Diagnostics, 2024)](https://www.mdpi.com/2075-4418/14/3/252)\n15. [How to do indocyanine green fluorescence-guided axillary sentinel lymph node biopsy in breast cancer: the sunrise effect (ANZ Journal of Surgery, 2025)](https://www.ovid.com/journals/anzsu/pdf/10.1111/ans.70122~how-to-do-indocyanine-green-fluorescenceguided-axillary)\n16. [99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization (JNMT)](https://tech.snmjournals.org/content/43/2/87)\n17. [Observations on a “sentinel node” in cancer of the parotid (Cancer, 1960)](https://doi.org/10.1002/1097-0142%28196001/02%2913:1<77::aid-cncr2820130114>3.0.co;2-d)\n18. [Current status of sentinel lymph node biopsy in solid malignancies (World Journal of Surgical Oncology, 2004)](https://wjso.biomedcentral.com/articles/10.1186/1477-7819-2-9)\n19. [JAN H. WONG, LESLIE A. CAGLE, DONALD L. MORTON (1991). Lymphatic Drainage of Skin to a Sentinel Lymph Node in a Feline Model. Annals of Surgery.](https://doi.org/10.1097/00000658-199111000-00015)\n20. [Donald L. Morton (1992). Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma. Archives of Surgery.](https://doi.org/10.1001/archsurg.1992.01420040034005)\n21. [Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications (A Cancer Journal for Clinicians, 2006)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/canjclin.56.5.292)\n22. [Armando E. Giuliano and colleagues (1994). Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. Annals of Surgery.](https://doi.org/10.1097/00000658-199409000-00015)\n23. [An Updated Review on the Emerging Role of Indocyanine Green (ICG) as a Sentinel Lymph Node Tracer in Breast Cancer (Cancers, 2023)](https://www.mdpi.com/2072-6694/15/24/5755)\n24. [Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis (PLOS One)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0155597)\n25. [Michael D. Alvarado and colleagues (2019). SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Annals of Surgical Oncology.](https://doi.org/10.1245/s10434-019-07577-4)\n26. [Sentinel Lymph Node Biopsy for Melanoma: ASCO–SSO Joint Clinical Practice Guideline](https://llusurgonc.org/images/DOWNLOADS/SENTINEL_ARTICLE/Melanoma/Nodal/SSO-ASCO-Melanoma-SLNB-guidelines_JCO2012.pdf)\n27. [Nynke S. van den Berg and colleagues (2012). Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-99mTc-nanocolloid. European Journal of Nuclear Medicine and Molecular Imaging.](https://doi.org/10.1007/s00259-012-2129-5)\n28. [Imaging-Based Approach to Axillary Lymph Node Staging and Sentinel Lymph Node Biopsy in Patients With Breast Cancer (AJR)](https://www.ajronline.org/doi/full/10.2214/AJR.19.22022)\n29. [Abigail S. Caudle and colleagues (2016). Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2015.64.0094)\n30. [Comparative analysis of indocyanine green and technetium-99m for sentinel lymph node localization in breast cancer (Frontiers in Oncology, 2026)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1817708/full)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Surgery and surgical specialties › Plastic, reconstructive, and oncologic surgery procedures*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026; Oct 21, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/lymph-node-mapping", "markdown_url": "https://www.edgepedia.org/lymph-node-mapping.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Lymph node mapping\", Edgepedia (EdgeChat), https://www.edgepedia.org/lymph-node-mapping. Edgepedia Community License 1.0.", "credit_md": "\"[Lymph node mapping](https://www.edgepedia.org/lymph-node-mapping)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/lymph-node-mapping](https://www.edgepedia.org/lymph-node-mapping). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Lymph node mapping\", Edgepedia (EdgeChat), https://www.edgepedia.org/lymph-node-mapping. Edgepedia Community License 1.0.", "speakable": "Lymph node mapping is a surgical and imaging technique that identifies the first lymph node draining a tumor, guiding biopsy and staging in breast cancer and melanoma." }